Home › NDC Lookup › RxCUI directory › RxCUI 1046654

Hypromellose 5 MG/ML / naphazoline hydrochloride 0.3 MG/ML Ophthalmic Solution — RxCUI 1046654

Name: Hypromellose 5 MG/ML / naphazoline hydrochloride 0.3 MG/ML Ophthalmic Solution (RxCUI 1046654)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 1046654 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1046654

Official nameHypromellose 5 MG/ML / naphazoline hydrochloride 0.3 MG/ML Ophthalmic Solution

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known ashypromellose 0.5 % / naphazoline hydrochloride 0.03 % Ophthalmic Solution; hypromellose 0.5 % / naphazoline HCl 0.03 % Ophthalmic Solution

FDA products mapped1

Package NDCs mapped1

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

🕸️ Concept Web — How Hypromellose 5 MG/ML / naphazoline hydrochloride... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Hypromellose 5 MG/ML / naphazoline hydrochloride 0.3 MG/ML Ophthalmic Solution RxCUI 1046654 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 4

The active substance itself — no strength, form, or brand attached yet.
- Hypromellose 27334 IN
- Naphazoline 7247 IN
- Hypromellose / naphazoline 690133 MIN
- Naphazoline hydrochloride 82054 PIN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Hypromellose / naphazoline Ophthalmic Solution 372996 SCDF
- Hypromellose / naphazoline hydrochloride Ophthalmic Solution 2647125 SCDFP
- Hypromellose / naphazoline Ophthalmic Product 1160116 SCDG
- Hypromellose / naphazoline hydrochloride Ophthalmic Product 2663190 SCDGP
- Ophthalmic Solution 7670 DF
- Ophthalmic Product 1151135 DFG
Clinical & branded drugs 2

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Hypromellose 5 MG/ML 358713 SCDC
- Naphazoline hydrochloride 0.3 MG/ML 1046650 SCDC

Showing up to 8 concepts per family — 12 of 12 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Hypromellose 5 MG/ML SCDC · 358713
Naphazoline hydrochloride 0.3 MG/ML SCDC · 1046650
Hypromellose / naphazoline Ophthalmic Solution SCDF · 372996
Hypromellose / naphazoline hydrochloride Ophthalmic Solution SCDFP · 2647125
Hypromellose / naphazoline Ophthalmic Product SCDG · 1160116
Hypromellose / naphazoline hydrochloride Ophthalmic Product SCDGP · 2663190

📦 FDA Products & Package NDCs

1 product · 1 package NDC

1 package NDC map to RxCUI 1046654 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
24208-0450-15	1 BOTTLE, DROPPER in 1 CARTON (24208-450-15) / 15 mL in 1 B...	Advanced Eye Relief/ Redness Maximum Relief	Bausch & Lomb Incorporated	2010-09-02

Observed labelers: Bausch & Lomb Incorporated (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.